Clinical trial KEYNOTEC93
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTEC93/GOG-3064/ENGOT-en15)
| Cancers | |
|---|---|
| Organ | Endometrium |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | MSD (Merck Sharp & Dohme) |
| EudraCT Identifier | 2021-003185-12 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05173987 |
| Last update |